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Abstract
Background: The systemic vascular response to hypoxia is vasodilation. However, reports suggest that the potent
vasoconstrictor endothelin-1 (ET-1) is released from the vasculature during hypoxia. ET-1 is reported to augment
superoxide anion generation and may counteract nitric oxide (NO) vasodilation. Moreover, ET-1 was proposed to
contribute to increased vascular resistance in heart failure by increasing the production of asymmetric
dimethylarginine (ADMA). We investigated the role of ET-1, the NO pathway, the potassium channels and radical
oxygen species in hypoxia-induced vasodilation of large coronary arteries.
Results: In prostaglandin F2a (PGF2a, 10 μM)-contracted segments with endothelium, gradual lowering of oxygen
tension from 95 to 1% O2 resulted in vasodilation. The vasodilation to O2 lowering was rightward shifted in
segments without endothelium at all O2 concentrations except at 1% O2. The endothelin receptor antagonist
SB217242 (10 μM) markedly increased hypoxic dilation despite the free tissue ET-1 concentration in the arterial wall
was unchanged in 1% O2 versus 95% O2. Exogenous ET-1 reversed hypoxic dilation in segments with and without
endothelium, and the hypoxic arteries showed an increased sensitivity towards ET-1 compared to the normoxic
controls. Without affecting basal NO, hypoxia increased NO concentration in PGF2a-contracted arteries, and an NO
synthase inhibitor, L-NOARG,(300 μM, NG-nitro-L-Arginine) reduced hypoxic vasodilation. NO-induced vasodilation
was reduced in endothelin-contracted preparations. Arterial wall ADMA concentrations were unchanged by
hypoxia. Blocking of potassium channels with TEA (tetraethylammounium chloride)(10 μM) inhibited vasodilation to
O2 lowering as well as to NO. The superoxide scavenger tiron (10 μM) and the putative NADPH oxidase inhibitor
apocynin (10 μM) leftward shifted concentration-response curves for O2 lowering without changing vasodilation to
1% O2. PEG (polyethylene glycol) catalase (300 u/ml) inhibited H2O2 vasodilation, but failed to affect vasodilation to
O2 lowering. Neither did PEG-SOD (polyethylene glycol superoxide dismutase)(70 u/ml) affect vasodilation to O2
lowering. The mitochondrial inhibitors rotenone (1 μM) and antimycin A (1 μM) both inhibited hypoxic
vasodilatation.
Conclusion: The present results in porcine coronary arteries suggest NO contributes to hypoxic vasodilation,
probably through K channel opening, which is reversed by addition of ET-1 and enhanced by endothelin receptor
antagonism. These latter findings suggest that endothelin receptor activation counteracts hypoxic vasodilation.
Background
The systemic vascular response to hypoxia is thought to
be vasodilation [1,2], although lowering oxygen (O2)
from 95% to 1-5% O2 either induced or enhanced con-
striction in canine [3,4] and sheep [1,5] large coronary
arteries, while moderate hypoxia (12-40%) O2 was
reported to induce transient contractions in human and
porcine coronary arteries, and only vasodilation in
response to anoxia [1,6]. Reports also indicate that the
potent vasoconstrictor endothelin-1 (ET-1) is released
from the vasculature during hypoxia [7,8]. ET-1 is criti-
cal in the development of cardiovascular diseases such
as pulmonary hypertension, atherosclerosis, hyperten-
sion, and heart failure where hypoxia is a central feature
[9]. ET-1 was reported to augment superoxide anion
generation in human endothelial cells, suggesting a
mechanism for enhanced susceptibility to atherosclerosis
[10], and it was found that asymmetric dimethylarginine
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(ADMA) and ET-1 levels correlate with the extent of
intimal hyperplasia [11]. Moreover, ET-1 was proposed
to contribute to increased vascular resistance in heart
failure by increasing the production of ADMA [12]. We
found that the plasma concentration of ADMA rises fol-
lowing coronary angioplasty in patients with myocardial
infarction and in patients with stable angina pectoris
which are events associated with localised and general
tissue hypoxia [13]. ET-1 may also counteract nitric
oxide (NO) vasodilation by increasing the levels of free
radical oxygen species [10,14,15]. Thus, superoxide
anions may react with NO to generate peroxynitrite
(ONOO-), and hence lower the NO concentration, or be
converted by superoxide dismutase to hydrogen perox-
ide [16]. Thus, many mechanisms have been suggested
to contribute to the hypoxic response in coronary
arteries. Therefore, we have revisited the role of
endothelial factors in the arterial response to hypoxia.
In the present study, we hypothesized that endothe-
lium-derived factors modulate hypoxic vasodilation in
large porcine coronary arteries. To address this hypoth-
esis the following measurements were performed: (1)
the role of endothelin was investigated by functional
studies in isolated coronary arteries and measurement of
ET-1 in the vascular wall, (2) the role of NO was evalu-
ated by use of NO synthase and guanylyl cyclase inhibi-
tors, and simultaneous measurements of the NO
concentration and vascular contractility were performed,
(3) ADMA levels in the vascular interstitial fluid were
measured, (4) the involvement of the endothelial cell
layer in acute hypoxic vasodilation was investigated by
oxygen lowering performed in coronary arteries with
and without endothelium, (5) involvement of potassium
channels was investigated by adding a potassium chan-
nel blocker, tetraethylammonium (TEA), (6) a role for
radical oxygen species was investigated by addressing
the effect of scavengers of superoxide and H2O2, as well
as inhibitors of the mitochondrial electron transport.
The precise oxygen tension in a large coronary artery
wall is relatively unknown. In large arterial preparations
e.g. rabbit and porcine aorta exposed to 21% O2, O2
tension was found to fall and reach very low levels in
media of the vascular wall [17]. Therefore, in the pre-
sent study we have chosen to gradually lower organ
bath oxygen tension from 95% O2 (722 mm Hg) to 1%
O2 (7.6 mm Hg).
Methods
Ethics Statement
Hearts from Landrace-Yorkshire hogs were obtained at
a local slaughterhouse. All experiments conformed to
the European Convention for the Protection of Verte-
brate Animals used for Experimental and other Scienti-
fic Purposes [18].
Tissue
Immediately after sacrifice the aorta was cannulated and
the coronary circulation perfused with physiological sal-
ine solution (PSS) containing glucose 5.5 mM, bubbled
with 5% CO2 in O2 and buffered with HEPES (for com-
position see [19]). The hearts were bathed in PSS at 5°C
for approximately 2 hours until the start of the experi-
ment. The left anterior descending coronary artery
(LAD) was carefully dissected and the proximal 3-4 cm
of the artery was left intact (pressure myograph) or cut
into a maximum of 4 segments each being 2 mm long,
and each of the segments was used in different treat-
ments. Therefore, each experiment equals one pig (wire
myograph). In some experiments the endothelium was
removed by gentle rubbing of the lumen with a thin
wooden stick.
Functional myograph studies
Coronary artery segments were mounted for isometric
tension recordings in a 4-chamber wire myograph
(DMT, Tissue Bath System 700MO, Aarhus, Denmark)
containing 5°C PSS bubbled with 95% O2, 5% CO2.
Temperature was raised to 37°C and the arteries were
normalized according to a standard procedure [20].
Arteries were allowed to equilibrate for approximately
30 minutes. Before running the experiment, preparation
viability was examined by exposing arteries to potas-
sium-rich PSS (K+PSS, 123.5 mM). The dilatory
response to hypoxia was evaluated following a stable
contractile response to prostaglandin F2a (PGF2a)
10 μM. After the experiment arteries were contracted
with PGF2a (10 μM) and removal of the endothelial
layer was evaluated by lack of response (<10% vasodila-
tion) to bradykinin 30 nM (see Figure 1). Appropriate
gas composition was obtained by mixing 95% O2, 5%
CO2 with 95% N2, 5% CO2 using a gasmixer (Digamix,
H. Wösthoff GmbH, Bochum, Germany). The organ
bath was bubbled through glass tubes with pimpstone
allowing rapid equilibration of the oxygen tension set by
the pump. The gas tension was set to 95% O2 (722 mm
Hg), 40% O2 (304 mm Hg), 20% O2 (152 mm Hg), 10%
O2 (76 mm Hg), 5% O2 (38 mm Hg), and 1% O2
(7,6 mm Hg). Oxygen concentration was measured with
an oxygen electrode (Unisense, Aarhus, Denmark), and
the measured oxygen concentrations were 92.4 ± 0.7%,
39.6 ± 0.4%, 20.2 ± 0.2%, 11.0 ± 0.2%, 5.8 ± 0.2%, and
1.2 ± 0.3% (n = 8).
The oxygen curve was performed by maintaining the
oxygen level at a fixed concentration until steady state
before changing to the next level. We investigated the
role of the endothelin receptor antagonist SB217242
(10 μM), the competitive NO synthase inhibitor NG-
nitro-L-Arginine (L-NOARG, 300 μM), the potassium-
selective ion channel blocker TEA (10 μM), the free
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radical scavenger tiron (10 μM), the putative NADPH
oxidase inhibitor apocynin (10 μM), the catalyst for
H2O2 decomposition PEG catalase (300 u/ml), the cata-
lyst for dismutation of superoxide PEG-SOD (70 u/ml),
and the mitochondrial inhibitors rotenone (1 μM), and
antimycin A (1 μM). These were incubated 30 minutes
prior to PGF2a contraction. We performed concentra-
tion-response curves for ET-1 (10-11 - 3 × 10-8 M), and
the influence of oxygen and NO on the arteries was
examined. In another set of experiments, the arteries
were normalized and tested for the presence of
endothelium before an inhibitor of guanylyl cyclase 1H-
[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) (3 μM)
was added and left until steady state before arteries
were contracted with either PGF2a (1 μM) or ET-1 in
appropriate amounts (1-10 nM) to reach similar levels
of contraction. Oxygen or NO concentration-response
curves were performed.
Tissue concentrations of ET-1 were determined in
arterial segments mounted in wire myographs and con-
tracted with 10 μM PGF2a, and exposed to hypoxia or
oxygenation for 60 min. After treatment the arteries
Figure 1 Original trace illustrating the relaxation induced by lowering the oxygen concentration . (A) Pig coronary artery with
endothelium, and (B) without endothelium. The arteries were contracted with PGF2a (10 μM), and O2 was gradually lowered, then the bath
solution was exchanged (wash), the artery was reoxygenated and after a new contraction with PGF2a endothelial function was evaluated by
adding bradykinin (30 nM).
Hedegaard et al. BMC Physiology 2011, 11:8
http://www.biomedcentral.com/1472-6793/11/8
Page 3 of 12
were frozen in cold acetone and dry ice at -78°C. Before
homogenization the tissue was allowed to equilibrate at
room temperature for 2 hours before the dried tissue
was weighed. The samples were homogenized in EIA
buffer from the ET-1 ELISA kit using a Precellys 24
homogenizer (Bertin Technologies, Montigny-le-Breton-
neux, France). The samples were exposed to 3 cycles at
5000 rpm for 30 seconds each. After homogenization
the samples were centrifuged at 10.000 rpm for 10 min
at 4°C, and the supernatant was collected and kept at
-80°C. The ET-1 content in each sample was quantified
with an ELISA assay (Immuno-Biological Laboratories
Co., Ltd, Japan) according to the manufacturer’s instruc-
tions. This assay is a solid phase sandwich ELISA using
2 kinds of highly specific antibodies. Tetra Methyl Ben-
zidine (TMB) was used as colouring agent (chromogen);
the strength of colouring was proportional to the quan-
tity of ET-1.
Simultaneous measurements of NO concentration and
force
For simultaneous measurement of force and NO con-
centration, an NO sensitive microelectrode (ISONOP30,
World Precision Instruments, Stevenage, UK) was used.
The calibration of the electrode was performed at 21%
and 1% O2 by use of an NO solution and then intro-
duced into the lumen of the artery mounted in a single
channel wire myograph as previously described [19,21].
To test selectivity of the electrodes, a lack of response
to sodium nitrite of up to 10 μM was regarded as evi-
dence for an intact coating of the electrode. Noradrena-
line is oxidized on carbon fibres if electrode coating is
damaged, and electrodes were discarded if noradrenaline
(0.5 μM), in the absence of vascular tissues, increased
electrode current.
Coronary arterial segments 2 mm in length were sus-
pended in a wire myograph (DMT, Tissue Bath System)
for force measurements and the microelectrode was
introduced into the lumen. To investigate the role of
basally-released NO, simultaneous measurements of
force and NO concentration were performed in both the
absence and presence of a scavenger of free NO, oxy-
haemoglobin (10 μM). To evaluate the effect of agonist
induced relaxation and NO release, artery rings were
contracted with PGF2a, 10 μM, and bradykinin was
added.
Functional testing and interstitial concentration of ADMA
Two cm long cylindrical arterial segments were mounted
at both ends on a stainless steel cannulae and fastened
with sutures in PSS bubbled with 5% CO2 in O2 in a
pressure myograph (110P XL, DMT). The temperature
was raised to 37C. Previous to the measurements the
segments were stretched to the in situ length using a
micrometer device. A transmural pressure of 40 mm Hg
was applied for a 1-hour stabilizing period as well as dur-
ing the experiments. We previously found this to be opti-
mal in terms of coronary arterial response to an agonist
in a pressure myograph [22]. The external diameter of
the arterial segment was automatically determined by
video imaging at a frequency of 20 Hz. The internal pres-
sure was controlled by adjustment of two reservoirs con-
taining PSS mounted on a pressure column and
connected to the cannulae. Pressure transducers close to
the “arterial” end of each cannula measured the internal
pressure. Transmural pressure, the outer diameter, and a
video image of the arterial segment were continuously
sampled and stored on computer (Myodaq software, ver-
sion 2.03, DMT). Before and after experiments the video
dimension analyser was calibrated by use of a 3000 ×
3000 μm2 phantom in the horizontal and vertical
directions.
After a stabilising period in the organ bath, artery tone
was induced with PGF2a. When a stable constriction
was established, hypoxia was induced by adjusting the
gas concentrations from 5% CO2 in O2 (organ bath
PO2>650 mm Hg, ISO2-D, WPI, Fl) to 5% CO2 in N2
resulting in 1% O2 in the organbath (PO2 30 mm Hg).
The influence of 60 min of hypoxia was studied. Oxyge-
nated conditions were re-established by switching back
to PSS equilibrated with 5% CO2 in O2 and the arterial
response during the following 60 min was recorded
(reoxygenation period). Organ bath pH was constant at
7.4.
In other experiments a microdialysis catheter (CMA/7,
CMA, Sweden) was placed in the smooth muscle inter-
stitium of a coronary artery mounted in the pressure
myograph as previously described [23]. The microdialy-
sis catheter has a 6 kDa molecular cut-off and an outer
diameter of 0.24 mm. Perfusion of the catheter was
started immediately after mounting at a rate of 0.3 μl/
min with isotonic saline. Thirty-minute samples of dialy-
sate (9 μl/sample) were collected. There was a delay of
12 min between the passage of the perfusate through
the microdialysis catheter and collection in vials. This
time delay was considered in the calculations and all
data are presented in real time. Microdialysis samples
were collected 60 min prior to hypoxia, during hypoxia,
and during reoxygenation. In a subset of experiments
ADMA 10 μM was added to the organ bath at baseline.
Concentrations of dialysate ADMA concentrations
were determined by high-performance liquid chromato-
graphy (HPLC, fluorescence detector) and precolumn
derivation with o-pthaldialdehyde according to previous
studies [24,25]. Standard curves for ADMA were con-
structed before each analysis.
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Statistics
Values are presented as mean ± SEM and number of
vessels (one per pig). Because the coronary artery dia-
meter varied between pigs, the steady state diameters
induced by PGF2a were used as an internal standard
(100%). Two-way analyses of variance and paired t-tests
were used to test for differences between groups. Differ-
ences were considered statistically significant when P <
0.05.
Results
In PGF2a (10 μM) contracted coronary arterial segments
with endothelium lowering of O2 resulted in a transient
increase in tension followed by relaxation which was
most pronounced at 1% O2 (Figure 1A). In segments
without endothelium, the concentration-response curve
for lowering O2 was rightward shifted (Figure 1B, Figure
2A), but the relaxation induced by 1% O2 was similar in
segments with (73.2 ± 7.2%, n = 5) and without
endothelium (75.0 ± 3.1%, n = 4). In a pressure myo-
graph, 1% O2 also increased diameter in segments with
endothelium (19.4 ± 2.7%, n = 14) to a similar degree as
in segments without endothelium (20.8 ± 2.6%, n = 14).
The endothelin receptor antagonist SB217242 signifi-
cantly increased hypoxic relaxation regardless of the
presence or absence of endothelium (Figure 2A). Addi-
tion of SB217242 to the organ bath resulted in less than
1% reduction in tone indicating limited ET-1 mediated
basal vasoconstrictor tone in the coronary arteries. Tis-
sue ET-1 was measured in arteries both with and with-
out endothelium exposed to 1 hour of hypoxia
compared to normoxic controls and no statistical differ-
ences in ET-1 concentration were found (Figure 2B).
ET-1 added to the organ bath in control experiments
could also be detected. Concentration response curves
were constructed for ET-1, and we found ET-1 reversed
vasodilation induced by 1% O2 in arteries with and with-
out endothelium. The sensitivity towards ET-1 was
increased at 1% O2 compared to 95% O2 both in arteries
with and without endothelium (Figure 2C).
Concentration-responses for exogenously added NO
were rightward shifted in coronary arterial segments
contracted to the same level with endothelin compared
to PGF2a (Figure 3A). In PGF2a and ET-1 contracted
arterial segments, an inhibitor of guanylyl cyclase, ODQ
(3 μM) inhibited the response to exogenously added NO
markedly (Figure 3A), but failed to change the response
to O2 lowering (Figure 3B). Coronary arterial relaxation
induced by O2 lowering from 95 to 1% O2 was reduced
after inhibition of nitric oxide synthase with L-NOARG
300 μM (Figure 3C).
Basal NO release was evaluated by the addition of a
scavenger of NO, oxyhaemoglobin (10 μM) and basal
release of NO was calculated as a reduction in electrode
Figure 2 Effect of the endothelin receptor antagonist
SB217242 on hypoxic vasodilation. (A) Effect of the endothelin
receptor antagonist SB217242 (10 μM) on concentration-response
curves for oxygen (O2) lowering in coronary arterial segments with
and without endothelium contracted with PGF2a (10 μM). (B) Tissue
ET-1 in arteries exposed to 1 h of hypoxia (5% CO2, 95% N2)
compared to normoxic controls. By adding ET-1 (10-7 M) to the
organ bath we were able to measure ET-1 (P < 0.001). (C)
Concentration-response curves for increasing concentrations of ET-1
in coronary artery segments with and without endothelium and
constricted with PGF2a (10 μM) and subsequently exposed to 1% O2
or 95% O2 for 30 min as well as during the rest of the experiments.
Results are means ± SEM of 4-9 experiments. Differences were
evaluated with two-way ANOVA followed by Bonferroni post-test: *
P < 0.05, ** P < 0.01, ***P < 0.001 compared to control.
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current as previously reported [19]. The procedure was
performed during both normoxic and hypoxic condi-
tions. There was no significant difference in basal
release of NO at 21% O2 (64.2 ± 16 nM, n = 6) versus
1% O2 (64.3 ± 14 nM, n = 5). In arteries contracted to
the same level by adding additional PGF2a (Figure 4A),
the NO concentration was markedly enhanced at 1% O2
compared to 21% O2 (Figure 4B). Dialysate concentra-
tions of the NO synthase inhibitor ADMA from arteries
investigated in normal HEPES were at the lower detec-
tion limit (<0.06 μM) and showed no tendency to
increase during hypoxia. We found that following the
addition of ADMA 10 μM to the organ bath, significant
amounts of ADMA could be recovered in the dialysate
and this was independent of oxygenation (21% O2: 1.9 ±
0.3 μM; 1% O2: 2.0 ± 0.3 μM, n = 6).
A non-specific potassium channel blocker, TEA signif-
icantly inhibited relaxation induced by O2 lowering (Fig-
ure 5A). Concentration-responses for exogenously added
NO were significantly inhibited in the presence of TEA
Figure 3 Role of the nitric oxide (NO)-cyclic GMP pathway in
hypoxic vasodilation. (A) Concentration-response curves for NO in
the absence and the presence of an inhibitor of soluble guanylyl
cyclase, ODQ (3 × 10-6 M) in arteries contracted with endothelin or
PGF2a. (B) Concentration-response curves for O2 lowering in the
absence and the presence of an inhibitor of soluble guanylyl
cyclase, ODQ (3 × 10-6 M) in arteries contracted with endothelin or
PGF2a (C) Concentration-response curves for O2 lowering in the
absence and the presence of an inhibitor of NO synthase, L-NOARG
(3 × 10-4 M). Results are means ± SEM of 6 experiments. Differences
were evaluated with two-way ANOVA with Bonferroni post-test: * P
< 0.05, ** P < 0.01, ***P < 0.001 compared to control.
Figure 4 Effect of acute hypoxia on nitric oxide release. Effect
of acute hypoxia (1% O2) on (A) constriction to PGF2a and (B) the
release of NO. Results are means ± SEM of 5 experiments.
Differences were evaluated with a paired t test: *P < 0.05 versus
control,
Hedegaard et al. BMC Physiology 2011, 11:8
http://www.biomedcentral.com/1472-6793/11/8
Page 6 of 12
(Figure 5B). A subanalysis showed that the presence of
ODQ (3 μM) together with TEA gave an additional
inhibition of NO induced relaxation as compared to
TEA alone at 10-5 and 3*10-5 M NO.
In arteries with endothelium, the transient contrac-
tions disappeared and a leftward shift in concentration-
response curves for O2 lowering was observed in seg-
ments treated with the superoxide scavenger, tiron,
while tiron had no effect in segments without endothe-
lium (Figure 6A). In arterial segments with endothelium,
an inhibitor of superoxide formation, apocynin leftward
shifted concentration-response curves for O2 lowering,
but this was not the case for arteries without endothe-
lium (Figure 6B). The vasodilation to 1% O2 was unal-
tered in the presence of either tiron or apocynin.
Additional tests of the potential role of H2O2 showed
that the cell permeable enzyme PEG catalase 300 u/ml
failed to change hypoxic relaxation (Figure 7A) while
H2O2 -induced relaxation was inhibited (Figure 7B). A
test for the potential role of superoxide showed that
PEG-SOD 70 u/ml failed to change the curves for O2
lowering (Figure 7C).
The mitochondrial inhibitors rotenone (1 μM) and
antimycin A (1 μM) both significantly inhibited vasodi-
latation to O2 lowering (Figure 8A). The combination of
the two inhibitors did not have an additional effect com-
pared to either of the inhibitors alone (Figure 8A). The
Figure 5 Effect of the potassium channel blocker TEA on
hypoxic vasodilation. (A) Concentration-response curves for O2
lowering in the absence and the presence of an inhibitor of soluble
guanylyl cyclase, ODQ (3 × 10-6 M) and the absence or presence of
the potassium channel blocker TEA (10 μM). (B) Concentration-
response curves for NO in the absence and the presence of an
inhibitor of soluble guanylyl cyclase, ODQ (3 × 10-6 M) and the
absence or presence of the potassium channel blocker TEA (10 μM).
Results are means ± SEM of 8 experiments. Differences were
evaluated with two-way ANOVA with Bonferroni post-test: * P <
0.05, ** P < 0.01, ***P < 0.001 compared to control.
Figure 6 Effect of the free radical scavenger tiron and the
putative NADPH oxidase inhibitor apocynin on hypoxic
vasodilation. Effect of (A) the free radical scavenger tiron (10 μM)
and (B) the putative NADPH oxidase inhibitor, apocynin (10 μM) on
concentration-response curves for oxygen lowering in coronary
arterial segments contracted with PGF2a (10 μM). Results are means
± SEM of 8-9 experiments. Differences were evaluated with two-way
ANOVA with Bonferroni post-test: * P < 0.05, ** P < 0.01, ***P <
0.001 compared to control.
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mitochondrial inhibitors did not change NO relaxation
(Figure 8B).
Discussion
There are three major findings of the present in vitro
investigation. First, endothelin receptor activation
reverses while endothelin receptor antagonism markedly
enhances hypoxic vasodilation in pig coronary arteries
with and without endothelium. These findings suggest
that endothelin counteracts hypoxic vasodilation in por-
cine coronary arteries independently of the endothelium.
Second NO release was augmented during hypoxia and
L-NOARG inhibited hypoxia-induced relaxation sug-
gesting that NO contributes to hypoxic relaxation. Since
a non-specific K channel blocker, TEA inhibited
Figure 7 Effect of PEG-catalase and PEG-SOD on hypoxic
vasodilation. (A) Effect of PEG-catalase (100 u/ml) on
concentration-response curves for oxygen lowering and (B) Effect of
PEG catalase (100 u/ml) on concentration-response curves for
hydrogen peroxide. (C) Effect of PEG-SOD (70 u/ml) on
concentration-response curves for oxygen lowering. Results are
means ± SEM of 8 experiments. Differences were evaluated with
two-way ANOVA followed by Bonferroni post-test: * P < 0.05, ** P <
0.01, ***P < 0.001 compared to control.
Figure 8 Effect of Rotenone and Antimycin A on hypoxic
vasodilation. Effect of rotenone (1 μM), antimycin A (1 μM), and
rotenone (1 μM)+ antimycin A (1 μM) on concentration-response
curves for (A) oxygen lowering and (B) Concentration-response
curves for NO. Results are means ± SEM of 9 experiments.
Differences were evaluated with two-way ANOVA followed by
Bonferroni post-test: * P < 0.05, ** P < 0.01, ***P < 0.001 compared
to control.
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relaxations induced by O2 lowering or NO, the counter-
acting effect of endothelin on hypoxic vasodilation may
take place through inhibition of K channels. Third,
there was no additional release of ADMA or indication
of additional release of oxygen free radicals during
severe hypoxia (5 and 1% O2).
Endothelin counteracts hypoxic vasodilation
Despite overall vasodilation to hypoxia, previous studies
report increased endothelial release of ET-1 in response
to hypoxia in systemic arteries [7,8], and hypoxia was
suggested to increase ET-1 levels in cultured human
umbilical venous endothelial cells exposed to 24 hours
of hypoxia [26]. In addition to the endothelium, forma-
tion of endothelin can also take place in smooth muscle
and adventitial cells of the vascular wall [27,28]. In the
present study we were able to measure changes in
endothelin concentration when it was added exogen-
ously, but we did not observe any difference in the
amount of ET-1 in porcine coronary arteries exposed to
hypoxia. We cannot exclude the possibility that stoi-
chiometric binding of endothelin may differ in normoxic
versus hypoxic situations. Previous studies in rats show
that most cardiac endothelin receptors are free of
bound endothelin [29] and that ischemia-reperfusion
increases ET-1 binding in rabbit hearts [30]. Such
changes would not have been reflected in tissue
endothelin concentrations as measured by our ELISA
assay. However, the mixed endothelin receptor antago-
nist SB217242 (enrasentan) increased relaxation regard-
less of the presence or absence of endothelium. In
previous studies we have found that endothelin contrac-
tion is antagonized by the ETA receptor antagonists
BQ123 as well as by SB217242 [31] in the porcine
coronary arteries [19].
Previous studies have suggested that exposure to
hypoxic conditions may enhance the response to
endothelin. Thus, in an in vitro study of pig coronary
subendocardial arterioles two weeks after myocardial
infarction an increased vasoconstrictor response to ET-1
was observed in vessels from animals with myocardial
infarction compared to vessels from control animals
[32], and an increased vasoconstriction to endothelin
was found in the coronary arteries after ischemia-reper-
fusion of the porcine heart [33]. In the present study,
addition of exogenous endothelin-1 reversed hypoxic
vasodilation and endothelin contraction was enhanced
in the arteries exposed to hypoxia. Together with
enhanced vasorelaxation in the presence of an endothe-
lin receptor antagonist, and the lack of change in vascu-
lar wall endothelin concentration, these findings suggest
that endothelin counteracts hypoxic vasodilation prob-
ably due to an increased endothelin receptor activation
of hypoxic arteries.
A non-endothelial origin of endothelin has previously
been suggested based on the observation that the ETA
antagonist BQ123 inhibited anoxic contractions in
canine coronary arteries without endothelium [4]. In the
present study, the non-endothelial origin of endothelin
is supported by our observation that an endothelin
receptor antagonist enhances relaxation to O2 lowering
in arteries without endothelium and that contribution of
endothelial-derived endothelin to the measured amount
of endothelin in the porcine coronary arteries was insig-
nificant (Figure 2).
Role of NO in hypoxic vasodilatation
Studies using both wire-based and pressurised in vitro
set-ups have found that inhibition of NO synthesis
reduces hypoxic vasodilation [34-37], although L-
NOARG had no effect on hypoxic relaxation in rat con-
duit coronary arteries [38]. Also, in vivo, Nase et al. [39]
measured NO release in rat intestinal arterioles by
means of microelectrodes and found a two-fold increase
in arteriolar NO concentration during oxygen reduction.
In the present study direct measurements of NO also
suggest that NO increases in contracted arteries exposed
to hypoxia. Together with the observation that the con-
centration-response curves for O2 lowering are right-
ward shifted by endothelial cell removal, and by an
inhibitor of NO synthase, L-NOARG, these findings
suggest that NO contributes to hypoxic vasodilation in
porcine coronary arteries. However, experiments in
arterial segments without endothelium or after inhibi-
tion of the NO-cGMP pathway in the present study,
also revealed that smooth muscle vasodilatory pathways
independent of the endothelial cell layer appear to con-
tribute to hypoxic vasodilation in porcine large coronary
arteries.
Following our recent findings that the plasma concen-
tration of the endogenous NO synthase inhibitor,
ADMA, rises in patients with myocardial infarction [13]
and that ADMA reduces coronary artery contraction to
hyperoxia [19] it was logical to investigate the role of
ADMA in hypoxic coronary dilation. We were able to
recover ADMA when it was added, but the concentra-
tion of ADMA was extremely low in coronary artery
interstitial fluid and did not rise during hypoxia. Addi-
tion of pathophysiologically relevant concentrations (10-
5 M, derived from our previous human study [13]) of
ADMA to the organ bath did not change the arterial
response to hypoxia. Moreover, these concentrations of
ADMA only cause incomplete inhibition of eNOS [21].
Therefore these findings suggest that ADMA in the
blood stream does not appear to play a role in hypoxia-
induced diameter changes.
It is well accepted that NO derived from the endothe-
lium or drugs promotes vascular relaxation through
Hedegaard et al. BMC Physiology 2011, 11:8
http://www.biomedcentral.com/1472-6793/11/8
Page 9 of 12
stimulation of soluble guanylate cyclase and generation
of cyclic GMP [40]. Hypoxia has also been found to
increase cyclic GMP formation in bovine pulmonary
arteries [41]. However, in contrast to inhibition of NO
synthase with L-NOARG, inhibition of soluble guanylate
cyclase by ODQ failed to reduce relaxations induced by
O2 lowering, although NO relaxations were reduced.
These findings suggest that endothelium-derived NO
in hypoxic conditions may cause guanylate cyclase-
independent relaxations.
The NO-cGMP pathway can lead to activation of
smooth muscle ATP-sensitive and large-conductance
calcium-activated K (BKCa) channels both through pro-
tein kinase G dependent and independent pathways
[42,43]. In the present study, the non-specific K channel
blocker TEA inhibited relaxations induced by O2 lower-
ing both in the absence and the presence of ODQ, and
also inhibited relaxations induced by exogenously added
NO. ODQ was reported to cause less inhibition of the
NO donor, S-nitroso-N-acetylpencillamin-induced
relaxation in bovine pulmonary arteries exposed to
hypoxia [41], and together with our finding that activa-
tion of TEA-sensitive channels is involved both in the
hypoxic and NO-induced relaxations in porcine coron-
ary arteries, these findings may suggest that K channels
are involved in the relaxations induced by the increased
NO observed in acute hypoxia, although other mechan-
ism such as NO-mediated inhibition of smooth muscle
sarcoplasmic Ca-ATPase may also contribute [41].
Endothelin has also been shown to inhibit KATP channel
conductance [44], and BK channels [45] in porcine cor-
onary artery smooth muscle cells. This latter effect of
endothelin may explain how hypoxic relaxation is coun-
teracted in porcine large coronary arteries.
Role of ROS and mitochondrial enzymes in hypoxic
vasodilation
ROS are natural by-products of the normal metabolism
of oxygen and are essential in cell signalling. ROS
include superoxide anion (O2
-), the electronically excited
singlet oxygen (1O2), hydrogen peroxide (H2O2), and
hydroxyl radical (OH). Saitoh et al. [46] suggested that
H2O2 is produced in a feed forward fashion in propor-
tion to cardiac metabolism and is directly coupled to
coronary blood flow [46]. Some studies support such a
feed forward theory [47,48] while results from other stu-
dies oppose it [49,50]. In this study ROS inhibition with
apocynin or tiron inhibited vasorelaxation to moderate
O2 levels (10% O2), but failed to alter porcine coronary
dilation in severe hypoxic conditions (1% O2). Moreover,
the effect of tiron and apocynin was only present in seg-
ments with endothelium suggesting that in moderate
hypoxic conditions ROS formation may counteract
hypoxic vasodilation by reacting with endothelium-
derived NO. Superoxide dismutase and catalase sca-
venge, respectively, extracellular O2
- and H2O2 and in
the pegylated forms, the penetration into the vascular
wall is increased of these molecules. However, PEG-
SOD and PEG-catalase failed to change relaxations
induced by O2 lowering, although PEG-catalase inhib-
ited exogenously added H2O2. These results agree with
recent findings in fetal chicken femoral arteries where
PEG-SOD and PEG-catalase also failed to change relaxa-
tion in severe hypoxia [51]. Although we cannot exclude
non-specific effects of tiron and apocynin [52,53], the
effects of both tiron and apocynin appear to be specific,
since the effects of moderate O2 levels are only observed
in segments with endothelium. Therefore, a likely expla-
nation for these results is that the reaction of NO and
O2
- to form ONOO- is too fast to allow the reaction of
O2
- with the antioxidant e.g. PEG-SOD in the vascular
wall [54]. However, overall the results of the present
study suggest that ROS do not appear to play a major
role in relaxations associated with severe hypoxia.
The mitochondrial electron transport chain is in
hypoxic conditions both considered as O2 sensor and a
source of NO accumulation due to decreased metaboli-
zation of NO by cytochrome C in a reduced state
[55,56]. Hypoxia-induced relaxations have previously
been reported to be reduced by inhibitors of the mito-
chondrial electron transport chain complex I (rotenone),
complex III (myxothiazole and antimycin A), and com-
plex IV (NaN3) [51,57]. In the present study both rote-
none and antimycin A reduced relaxation induced by
O2 lowering. Rotenone and antimycin A were also
found to increase formation of O2
- in bovine coronary
arteries [57]. However, in the present study rotenone
and antimycin A did not change relaxations induced by
exogenously added NO, and hence NO bioavailability.
Therefore, our results do not suggest a role for ROS in
severe hypoxia in porcine coronary arteries. Thus, our
results agree with observations in bovine coronary
arteries that ROS are not primary mediators of the
hypoxic relaxation, but sustain the presence of an O2
sensing/signaling model based on mitochondrial control
of pyruvate metabolism associated with cytosolic
NADPH redox regulation [55,57]. In addition to the
mitochondrial O2 sensing/signaling in smooth muscle
relaxation, our findings of increased NO formation in
hypoxic conditions (Figure 4), support an endothelial
mitochondrial sensing mechanism leading to increased
NO formation.
Conclusions
The present results in porcine coronary arteries suggest
NO contributes to hypoxic vasodilation, probably
through the K channels, which is reversed by addition
of ET-1 and enhanced by endothelin receptor
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antagonism. These latter findings suggest that endothe-
lin receptor activation counteracts hypoxic vasodilation.
The dilatory response to hypoxia is important in the
resistance arteries of the coronary circulation, but the
dilatory response to hypoxia is also present in conduit
vessels [1,58,59]. Combined with the fact that coronary
atherosclerosis is confined to epicardial arteries, even
minor diameter changes become highly important when
a hemodynamically significant stenosis is present. In
quantitative terms other scientific groups as well as our-
selves typically find a 20% increase in conductance cor-
onary artery diameter during hypoxia (the pressure
myograph findings in this study). According to Poi-
seuille’s law this equals a doubling in flow rate. In heart
disease hypoxia is also a prominent feature of heart fail-
ure, but while local hypoxia may alter cellular function
in the myocardium, systemic hypoxia may improve ven-
tricular function secondary to changes in vascular tone
[60]. In the atherosclerotic human coronary circulation
endothelium-dependent vasodilation is impaired [61]
and this is associated with an increased frequency of
cardiac events. Release of endothelium-derived NO is
decreased in endothelial dysfunction and could thus not
contribute to hypoxic vasodilation and counteract the
contractile effect of ET-1. Based on the present preclini-
cal findings it would be interesting to investigate the
therapeutic potential of endothelin receptor antagonists
in ischemic heart disease although unexpected hemody-
namic changes have been reported previously [62].
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